Dr. Reddy’s Laboratories’ API manufacturing plant at Srikakulam (SEZ) in state of Andhra Pradesh has completed the audit by the US Food and Drug Administration (USFDA) on April 14, 2017 with no observations.
Besides, the company is recalling 1,728 bottles of Rivastigmine Tartrate capsules, used for treatment of dementia, due to cross-contamination with other products from the US market. The company’s US arm, Dr. Reddy’s Laboratories Inc is recalling Rivastigmine Tartrate capsules 1.5 mg in 60-count bottle manufactured by the company in India.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
